Allometric prediction of the human pharmacokinetic parameters for naveglitazar

被引:0
作者
Ahlawat, Preeti [1 ]
Srinivas, Nuggehally R. [1 ]
机构
[1] ClinIec India Int Pvt Ltd, Global Drug Dev, Bangalore 560078, Karnataka, India
关键词
Naveglitazar; ragaglitazar; muraglitazar; pharmacokinetic parameters; humans; allometric prediction;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Compounds that belong to the class known its dual (alpha,gamma) peroxisome proliferator-activated receptors (PPARs) show interesting, pharmacological properties - regulation of blood glucose, fatty acids, and lipid parameters. Using the recently published preclinical data of naveglitazar. an allometric method was used to predict the human pharmacokinetic parameters (CL/F and Vss/F). The predicted parameters were compared to observed/predicted values of other important dual (alpha,gamma) PPAR compounds. The allometry dual suggested that naviglitazar (CL/F) was at least 4 times faster than that of ragaglitazar, while the Vss was either equal to or 40% lower as compared to that of ragaglitazar.
引用
收藏
页码:187 / 190
页数:4
相关论文
共 14 条
[1]   Effective care of patients with type 2 diabetes and dyslipidemia: A nurse's perspective [J].
Adiseshiah, M .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2005, 68 :S23-S27
[2]  
Blaha MJ, 2008, MAYO CLIN PROC, V83, P932, DOI 10.4065/83.8.932
[3]   ESTIMATION OF TOTAL HEPATIC BLOOD-FLOW BY DUPLEX ULTRASOUND [J].
CARLISLE, KM ;
HALLIWELL, M ;
READ, AE ;
WELLS, PNT .
GUT, 1992, 33 (01) :92-97
[4]   Muraglitazar: An agent for the treatment of type 2 diabetes and associated dyslipidemia [J].
Cox, SL .
DRUGS OF TODAY, 2005, 41 (09) :579-587
[5]   Prediction of human pharmacokinetics - renal metabolic and excretion clearance [J].
Fagerholm, Urban .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2007, 59 (11) :1463-1471
[6]   PPAR modulators and PPAR pan agonists for metabolic diseases: The next generation of drugs targeting Peroxisome Proliferator-Activated Receptors? [J].
Feldman, P. L. ;
Lambert, M. H. ;
Henke, B. R. .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2008, 8 (09) :728-749
[7]   Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) α and γ activator, in mice, rats, dogs, and monkeys [J].
Hosagrahara, V. P. ;
Chandrasena, G. ;
Chang, S. Y. ;
Koplowitz, B. ;
Hariharan, N. ;
Cheng, P. T. W. ;
Humphreys, W. Griffith .
XENOBIOTICA, 2006, 36 (12) :1227-1238
[8]  
Jiamsripong Panupong, 2008, Prev Cardiol, V11, P155
[9]   Interspecies allometric scaling. Part I: prediction of clearance in large animals [J].
Mahmood, I. ;
Martinez, M. ;
Hunter, R. P. .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2006, 29 (05) :415-423
[10]   Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator [J].
Pavankuamr, Venkata V. ;
Vinu, C. A. ;
Mullangi, Ramesh ;
Srinivas, Nuggehally R. .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2007, 32 (01) :29-37